Buy Stocks Easy | About Us
January 28, 2021
Buy Stocks Easy | Online Stocks

MNLO


Buy Menlo Therapeutics Inc. Stock (symbol: MNLO) Easy Online

Company Name: Menlo Therapeutics Inc.

Symbol: MNLO

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2018

MNLO Current Share Price

Today's MNLO ( Menlo Therapeutics Inc. ) opening price: $4.8900

Yesterday's MNLO ( Menlo Therapeutics Inc. ) closing price: $4.8900

Menlo Therapeutics Inc. Stock ( symbol: MNLO ) Price Chart since IPO (2018):

12 Months Menlo Therapeutics Inc. Stock ( symbol: MNLO ) Price Chart

Popular Questions about Menlo Therapeutics Inc. Public Stock ( MNLO )

A: Menlo Therapeutics Inc. stock symbol (also called stock or share ticker) is MNLO

A: Menlo Therapeutics Inc. IPO (Initial Public Offering) took place on 2018

A: Menlo Therapeutics Inc.'s stock (MNLO symbol) price at ther IPO (initial Public Offering) was $4.8900

Q: Is MNLO stock worth buying at the moment?

A: The MNLO stock performance since 2019 are rather disappointing. If you had bought 1 share of Menlo Therapeutics Inc. stock (symbol: MNLO) at the beginning of 2019, at the opening share price of $5.3500, you would be left with exactly $4.8900 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Menlo Therapeutics Inc. Stock Easy Online

Menlo Therapeutics Inc. Stock Ticker Price Chart since IPO:





Menlo Therapeutics Inc. Stock Price Yesterday



 


Menlo Therapeutics Inc. Stock Price – Last Week




 


Menlo Therapeutics Inc. Stock Price – Last Month




 


Menlo Therapeutics Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            https://seekingalpha.com/article/4305713-foamix-pharmaceuticals-ltd-fomx-ceo-dave-domzalski-q3-2019-earnings-and-merger-announcement
                            

                                
Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Earnings & Merger Announcement with Menlo Therapeutics Conference (Transcript)

                                
                                
Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Ea...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/11/1944604/0/en/Foamix-and-Menlo-Therapeutics-to-Merge-Creating-a-Combined-Company-Focused-on-the-Development-and-Commercialization-of-Therapeutics-for-Dermatologic-Indications.html
                            

                                
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

                                
                                
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Nov.  ...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4301190-menlo-therapeutics-serlopitant-pruritogenic-prurigo-nodularis-track
                            

                                
Menlo Therapeutics And Serlopitant In Pruritogenic Prurigo Nodularis: On Track

                                
                                
Pruritogenic responses usually evolve from chronic diseases predomi...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/29/1936897/0/en/Menlo-Therapeutics-Announces-Completion-of-Enrollment-in-Two-Phase-3-Trials-of-Serlopitant-in-Prurigo-Nodularis.html
                            

                                
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

                                
                                
- Pivotal results expected in March/April 2020 -


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/22/1933217/0/en/Menlo-Therapeutics-to-Host-Investor-Day-October-29-2019.html
                            

                                
Menlo Therapeutics to Host Investor Day October 29, 2019

                                
                                
-Management to Review Late Stage Development, NDA-readiness and Com...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/11/1928626/0/en/Menlo-Therapeutics-Presents-Successful-Phase-2-Clinical-Trial-Results-of-Serlopitant-in-Psoriasis-at-the-European-Academy-of-Dermatology-and-Venereology-Meeting.html
                            

                                
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

                                
                                
REDWOOD CITY, Calif., Oct.  11, 2019  (GLOBE NEWSWIRE) -- Menlo The...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921572/0/en/Menlo-Therapeutics-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference.html
                            

                                
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

                                
                                
REDWOOD CITY, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Menlo Th...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/535911/menlo-mnlo-completes-enrollment-in-phase-ii-pruritus-study
                            

                                
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

                                
                                
Menlo (MNLO) completes enrollment in the phase II study evaluating ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/24/1920293/0/en/Menlo-Therapeutics-Announces-Completion-of-Enrollment-of-233-Patients-in-Phase-2-Trial-of-Serlopitant-in-Patients-with-Chronic-Pruritus-of-Unknown-Origin.html
                            

                                
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

                                
                                
- Results expected in Q1 2020 -


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.